Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Lung Cancer

Bringing Hope to Patients with Stage IV Non–Small-Cell Lung Cancer
Dr. Sharon explains the impact of biomarker testing and targeted therapies on patients with non–small-cell lung cancer, highlighting the importance of personalized medicine in lung cancer. Read More ›

Enhertu First Drug Approved for Advanced Lung Cancer and HER2 Gene Mutation

How My Metastatic Lung Cancer Diagnosis Struck a New Chord in Me
When singer-songwriter Josh Colow started losing weight, feeling nauseous, and had a fever that wouldn’t go away, the last thing on his mind was lung cancer. Find out how his devastating diagnosis changed his attitude and perspective. Read More ›

Opdivo plus Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage Non–Small-Cell Lung Cancer

Looking at Lung Cancer without Stigma
In her introduction to this special issue on Lung Cancer, Lillie emphasizes that we need to inspire and help people to stop smoking, and get rid of the overall stigma surrounding this disease. Read More ›

Becoming a Patient Advocate After a Small-Cell Lung Cancer Diagnosis at Age 28
Montessa Lee’s pain persisted after an initial visit to the doctor and a misdiagnosis. Finally, an x-ray in the emergency room revealed a 15-cm mass on her left lung. Read how she turned anger into action. Read More ›

Immunotherapy Beneficial in Patients with Early-Stage Non–Small-Cell Lung Cancer and PD-L1 Expression
For the first time, the use of immunotherapy after surgical removal of the tumor and chemotherapy has shown benefits in patients with early-stage non–small-cell lung cancer (NSCLC) and PD-L1 expression, a biomarker found in some patients with NSCLC. Read More ›

Tecentriq First Immunotherapy Approved for Adjuvant Treatment of Patients with Early-Stage NSCLC and PD-L1 Expression
On October 15, 2021, the FDA approved a new indication for Tecentriq (atezolizumab) for adjuvant (additional) treatment of patients with stage II-IIIA non–small-cell lung cancer and PD-L1 expression, after surgical removal of the tumor and chemotherapy. This is the first immunotherapy approved for patients with early-stage lung cancer. Read More ›

The Pandemic Is Not Over: Staying Connected and Receiving Encouragement While Living with Lung Cancer
On his lonely journey dealing with lung cancer, Ron Simmons found that connecting with others who had lung cancer helped him create a sense of purpose and gave him a mission moving forward. Read More ›

Exkivity Second FDA-Approved Oral Targeted Therapy for Patients with Metastatic NSCLC and EGFR Exon 20 Insertion Mutations
On September 15, 2021, the FDA approved Exkivity (mobocertinib) capsules, an oral kinase inhibitor, for the treatment of adults with locally advanced or metastatic non–small-cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed during or after platinum-based chemotherapy, a cancer with few treatment options. Read More ›

Page 2 of 12